Those who applied for
Congratulations to everyone who applied for the free trial.
※ For those who missed the “COVID-19 treatment,” it’s okay. We are going out big once again.
※ Finally starting. Innotherapy(246960) follow-up stock hits the upper limit price on Tuesday ※
Research on genetic mutations in severe COVID-19 patients found a common ability to evade antiviral responses in the body. This is evaluated as providing direction for drug development!!
Interferon is a type of cytokine, a protein secreted by cells to transmit signals between immune cells or regulate immune responses, and is a glycoprotein that helps activate immune defense when viruses invade!!
“I applied and bought every day for 3 days, and I was amazed to see upper limit price profits every day. I wondered if it was a dream or reality. It’s really amazing how this can happen. It’s been about 4 months since I paid the membership fee and received VIP service, and already 56 million KRW has accumulated in my account. I’m really grateful for making me earn every day. Ah! I’m also actively recommending it to my acquaintances.” (VIP member Kim Cheol-gi, 56 years old)
▶▶ “September 29 upper limit price” offered only until today and then closed.
[Receive ‘COVID-19 interferon response evasion’ related stocks!] ▶Receive stocks◀
Think of this as the last chance. If you miss this opportunity, you have to give up.
Exactly “September 29” will explode! Don’t miss it and regret it, buy at least 1 million KRW!
▶▶ Only 30 people will be given. “Tuesday upper limit price”! ▶Receive now◀
※ First-come, first-served 30 people closed! Both early and late rounds are over. The hero of the last injury time winning goal ※
[Today’s stocks of interest]
#BaxelBio #Vinex #KainosMed #BukwangPharmaceutical #CelltrionHealthcare
※ This content is unrelated to Asia Economy’s editorial direction, and all responsibility lies with the information provider.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
